CMV-CTL for the Treatment of CMV Infection After HSCT

Status Completed

Clinical Trial Summary

Human cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT). we propose to study the immunologic and virologic effects of donor derived CMV specific cytotoxic T lymphocyte (CMV-CTL) given to transplant recipients CMV antigen peptides will be used to induce the CMV antigen specific T lymphocytes derived from donor peripheral blood mononuclear cells for a period of 18~21 days.The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA level will be monitored weekly after transfusion.

Clinical Trial Description

Allogeneic hematopoietic stem cell transplantation is widely used for the treatment of hematological malignancies and bone marrow failure diseases. Human cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT). Approximately half of the recipients would develop CMV infection after transplant. Present treatment recommendation for CMV infection including ganciclovir and foscarnet. However, these medications have many side effects, the most serious is myelosuppression and renal injury, moreover, many patients do not response to these medications. Considering the risk associated with persistent infection and the potential for CMV specific cytotoxic T lymphocyte (CMV-CTL) to restore immunity, we propose to study the immunologic and virologic effects of donor derived CMV-CTL given to transplant recipients, levels of CMV-CTL and CMV DNA will be measured from CTL recipients. If the patient and their donor are eligible, we will take 80 ml of fresh blood from the donor or 5 ml peripheral blood stem cell from the donor.The peripheral blood mononuclear cells will be separated from peripheral blood or peripheral blood stem cell. CMV antigen peptides will be used to induce the CMV-CTL for a period of 18~21 days. The donor derived CMV-CTL cells will be transfused into the patients' intravenous line. The patients will receive the dose of CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA levels will be monitored weekly for at least 60 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive one additional injection of CTLs. If the CMV levels in the blood continue to rise after the dose of T cells then the patient will receive treatment with Ganciclovir, Foscarnet. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03004261
Study type	Interventional
Source	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status	Completed
Phase	Phase 4
Start date	November 2016
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03950414` - A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients	Phase 1
Recruiting	`NCT04690933` - AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Withdrawn	`NCT04936971` - Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response	Phase 4
Recruiting	`NCT02671318` - Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence	Phase 4
Completed	`NCT01325636` - Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus	Phase 1/Phase 2
Recruiting	`NCT00228202` - Genotyping of Cytomegalovirus From Patients in Israel	N/A
Completed	`NCT00031421` - Neonatal CMV-Ganciclovir Follow-up Study	N/A
Completed	`NCT00005496` - Inflammation, Infection, and Future Cardiovascular Risk	N/A
Terminated	`NCT03262194` - Relevance of Gastric Aspirate in HCMV Detection
Completed	`NCT04478474` - Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
Recruiting	`NCT05370976` - Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.	Phase 2
Active, not recruiting	`NCT02943057` - Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis	Phase 4
Completed	`NCT02538172` - Cell-mediated Immunity for Prevention of CMV Disease	N/A
Completed	`NCT02642822` - The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University	N/A
Completed	`NCT02134184` - The Influence of Chronic CMV Infection on Influenza Vaccine Responses	Phase 4
Completed	`NCT00673868` - Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants	Phase 1
Active, not recruiting	`NCT05089630` - A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults	Phase 1/Phase 2
Not yet recruiting	`NCT06058858` - Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Active, not recruiting	`NCT04904614` - Letermovir Use in Heart Transplant Recipients	Phase 4
Completed	`NCT01986010` - Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)	Phase 1